Mutya Harsch
General Counsel chez VYNE THERAPEUTICS INC.
Fortune : 458 271 $ au 31/03/2024
Profil
Mutya Harsch is currently the Director at VYNE Pharmaceuticals Ltd.
and also holds the position of Secretary, Chief Legal Officer & General Counsel at VYNE Therapeutics, Inc. Previously, Ms. Harsch served as an Independent Director at Satsuma Pharmaceuticals, Inc. and as Secretary, Chief Legal Officer & General Counsel at Menlo Therapeutics, Inc. Ms. Harsch also worked as an Assistant General Counsel at Warner Chilcott, Inc. from 2003 to 2005 and as Special Counsel-Mergers & Acquisitions at Cooley LLP from 2015 to 2017.
Additionally, Ms. Harsch held the role of Chief Legal Officer & General Counsel at VYNE Pharmaceuticals, Inc. from 2018 to 2020.
Ms. Harsch completed undergraduate and graduate degrees at the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VYNE THERAPEUTICS INC
1,06% | 01/04/2024 | 149 274 ( 1,06% ) | 458 271 $ | 31/03/2024 |
Postes actifs de Mutya Harsch
| Sociétés | Poste | Début |
|---|---|---|
| VYNE THERAPEUTICS INC. | General Counsel | 01/03/2020 |
VYNE Pharmaceuticals Ltd.
 VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | Director/Board Member | 09/03/2020 |
Anciens postes connus de Mutya Harsch
| Sociétés | Poste | Fin |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Director/Board Member | 08/06/2023 |
VYNE Pharmaceuticals, Inc.
 VYNE Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals, Inc. manufactures pharmaceutical products. The company was founded on May 6th, 2014 and is headquartered in Bridgewater, NJ. | General Counsel | 01/03/2020 |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2017 |
Warner Chilcott, Inc.
 Warner Chilcott, Inc. Pharmaceuticals: MajorHealth Technology Warner Chilcott, Inc. develops and manufactures drugs. It makes women's health care and urology prescription drugs, dermatology and cardiology drugs. The company is headquartered in Rockaway, NJ. | Corporate Officer/Principal | 01/01/2005 |
| VYNE THERAPEUTICS INC. | General Counsel | - |
Formation de Mutya Harsch
| University of California, Berkeley | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VYNE THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | Health Technology |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
Warner Chilcott, Inc.
Warner Chilcott, Inc. Pharmaceuticals: MajorHealth Technology Warner Chilcott, Inc. develops and manufactures drugs. It makes women's health care and urology prescription drugs, dermatology and cardiology drugs. The company is headquartered in Rockaway, NJ. | Health Technology |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Commercial Services |
VYNE Pharmaceuticals, Inc.
VYNE Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals, Inc. manufactures pharmaceutical products. The company was founded on May 6th, 2014 and is headquartered in Bridgewater, NJ. | Health Technology |
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
